• Verzenio (abemaciclib) nabs FDA approval for HR+ HER2- High Risk Early Breast Cancer

    INDIANAPOLIS, Oct. 13, 2021 The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), in combination with endocrine therapy (tamoxifen or an aromatase inhibitor), for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early…